---
title: "Protalix Biotherap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 33.75 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286246719.md"
datetime: "2026-05-13T10:59:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286246719.md)
  - [en](https://longbridge.com/en/news/286246719.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286246719.md)
---

# Protalix Biotherap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 33.75 M

Revenue: As of FY2026 Q1, the actual value is USD 33.75 M, beating the estimate of USD 11.47 M.

EPS: As of FY2026 Q1, the actual value is USD 0.22.

EBIT: As of FY2026 Q1, the actual value is USD 21.15 M.

#### Total Revenue

Total revenue for Protalix BioTherapeutics, Inc. was $33.75 million for the first quarter of 2026, a significant increase from $10.113 million for the first quarter of 2025.

#### Segment Revenue

-   Revenues from selling goods were $7.419 million for the three months ended March 31, 2026, a decrease from $9.995 million for the same period in 2025. This change was primarily due to a timing shift in Pfizer’s purchases, partially offset by $3.5 million in sales to Chiesi that did not occur in the prior-year period.
-   Revenues from license and R&D services were $26.331 million for the first quarter of 2026, a significant increase from $0.118 million for the first quarter of 2025. This increase primarily resulted from a $25.0 million milestone payment received from Chiesi in connection with the approval of the E4W dosage in the European Union.

#### Operating Costs

-   Cost of revenues was $4.127 million for the first quarter of 2026, a decrease of $4.053 million (50%) compared to $8.180 million for the same period in 2025. This decrease was mainly attributed to lower sales volumes to Pfizer and Fiocruz, partially offset by increased sales to Chiesi.
-   Research & development (R&D) expenses were $5.426 million for the first quarter of 2026, an increase of $1.951 million (56%) compared to $3.475 million for the first quarter of 2025. This rise was primarily driven by preparations for and initiation of the Phase 2 RELEASE clinical trial of PRX-115.
-   Selling, general, and administrative (SG&A) expenses were $3.051 million for the first quarter of 2026, an increase of $0.448 million (17%) compared to $2.603 million for the prior-year period. The increase was primarily due to higher salary and related expenses.

#### Operating Income

Operating income for the first quarter of 2026 was $21.146 million, a significant improvement from an operating loss of - $4.145 million for the same period in 2025.

#### Net Income

Net income for Protalix 生物治疗 for the three months ended March 31, 2026, was $18.317 million, compared to a net loss of - $3.619 million for the same period in 2025. The net income was primarily driven by the milestone revenue recognized from Chiesi.

#### Other Financial Items

-   Financial income (expenses), net was - $0.005 million for the first quarter of 2026, compared to an income of $0.413 million for the first quarter of 2025.
-   Taxes on income were $2.824 million for the first quarter of 2026, compared to a tax benefit of - $0.113 million for the first quarter of 2025.
-   Cash, cash equivalents, and short-term bank deposits were $51.1 million as of March 31, 2026.

#### Outlook / Guidance

Protalix BioTherapeutics, Inc. reaffirms its 2026 revenue guidance, expecting total revenue to range from $78.0 million to $83.0 million, which includes a $25.0 million milestone from Chiesi. Full-year 2026 revenues from sales of Elfabrio are projected to be between $33.0 million and $35.0 million, while Elelyso sales are anticipated to range from $20.0 million to $23.0 million. The company also expects top-line results for the PRX-115 Phase 2 study in the second half of 2027.

### Related Stocks

- [PLX.US](https://longbridge.com/en/quote/PLX.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)